Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 901 to 904 of 904 entries
Sorted by: Best Match Show Resources per page
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.

Cell

Morad G, Helmink BA, Sharma P, Wargo JA.
PMID: 34624224
Cell. 2021 Oct 14;184(21):5309-5337. doi: 10.1016/j.cell.2021.09.020. Epub 2021 Oct 07.

Unprecedented advances have been made in cancer treatment with the use of immune checkpoint blockade (ICB). However, responses are limited to a subset of patients, and immune-related adverse events (irAEs) can be problematic, requiring treatment discontinuation. Iterative insights into...

Cite
Morad G, Helmink BA, Sharma P, et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309-5337doi: 10.1016/j.cell.2021.09.020.
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021). Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell, 184(21), 5309-5337. https://doi.org/10.1016/j.cell.2021.09.020
Morad, Golnaz, et al. "Hallmarks of response, resistance, and toxicity to immune checkpoint blockade." Cell vol. 184,21 (2021): 5309-5337. doi: https://doi.org/10.1016/j.cell.2021.09.020
Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021 Oct 14;184(21):5309-5337. doi: 10.1016/j.cell.2021.09.020. Epub 2021 Oct 07. PMID: 34624224.
Copy Download .nbib Format: NLM
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy.

Nature medicine

Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, Teruya-Feldstein J, Crary JF, Fowkes ME, Stacy CB, Kim-Schulze S, Rahman A, Laganà A, Brody JD, Merad M, Jagannath S, Parekh S.
PMID: 34893771
Nat Med. 2021 Dec;27(12):2099-2103. doi: 10.1038/s41591-021-01564-7. Epub 2021 Dec 10.

B-cell maturation antigen (BCMA) is a prominent tumor-associated target for chimeric antigen receptor (CAR)-T cell therapy in multiple myeloma (MM). Here, we describe the case of a patient with MM who was enrolled in the CARTITUDE-1 trial ( NCT03548207...

Cite
Van Oekelen O, Aleman A, Upadhyaya B, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27(12):2099-2103doi: 10.1038/s41591-021-01564-7.
Van Oekelen, O., Aleman, A., Upadhyaya, B., Schnakenberg, S., Madduri, D., Gavane, S., Teruya-Feldstein, J., Crary, J. F., Fowkes, M. E., Stacy, C. B., Kim-Schulze, S., Rahman, A., Laganà, A., Brody, J. D., Merad, M., Jagannath, S., & Parekh, S. (2021). Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nature medicine, 27(12), 2099-2103. https://doi.org/10.1038/s41591-021-01564-7
Van Oekelen, Oliver, et al. "Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy." Nature medicine vol. 27,12 (2021): 2099-2103. doi: https://doi.org/10.1038/s41591-021-01564-7
Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, Teruya-Feldstein J, Crary JF, Fowkes ME, Stacy CB, Kim-Schulze S, Rahman A, Laganà A, Brody JD, Merad M, Jagannath S, Parekh S. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021 Dec;27(12):2099-2103. doi: 10.1038/s41591-021-01564-7. Epub 2021 Dec 10. PMID: 34893771; PMCID: PMC8678323.
Copy Download .nbib Format: NLM
Risk factors for intraoperative complications in pheochromocytomas.

Endocrine-related cancer

Araujo-Castro M, Garcia Centeno R, López-García MC, Lamas C, Álvarez-Escolá C, Calatayud Gutiérrez M, Blanco-Carrera C, de Miguel Novoa P, Valdés N, Gracia Gimeno P, Fernández-Ladreda MT, Mínguez Ojeda C, Percovich Hualpa JC, Mora M, Vidal Ó, Serrano Romero A, Hanzu FA, Gómez Dos Santos V.
PMID: 34379605
Endocr Relat Cancer. 2021 Sep 08;28(11):695-703. doi: 10.1530/ERC-21-0230.

We aimed to identify presurgical and surgical risk factors for intraoperative complications in patients with pheochromocytomas. A retrospective study of patients with pheochromocytomas who underwent surgery in ten Spanish hospitals between 2011 and 2021 was performed. One hundred and...

Cite
Araujo-Castro M, Garcia Centeno R, López-García MC, et al. Risk factors for intraoperative complications in pheochromocytomas. Endocr Relat Cancer. 2021;28(11):695-703doi: 10.1530/ERC-21-0230.
Araujo-Castro, M., Garcia Centeno, R., López-García, M. C., Lamas, C., Álvarez-Escolá, C., Calatayud Gutiérrez, M., Blanco-Carrera, C., de Miguel Novoa, P., Valdés, N., Gracia Gimeno, P., Fernández-Ladreda, M. T., Mínguez Ojeda, C., Percovich Hualpa, J. C., Mora, M., Vidal, �. �., Serrano Romero, A., Hanzu, F. A., & Gómez Dos Santos, V. (2021). Risk factors for intraoperative complications in pheochromocytomas. Endocrine-related cancer, 28(11), 695-703. https://doi.org/10.1530/ERC-21-0230
Araujo-Castro, Marta, et al. "Risk factors for intraoperative complications in pheochromocytomas." Endocrine-related cancer vol. 28,11 (2021): 695-703. doi: https://doi.org/10.1530/ERC-21-0230
Araujo-Castro M, Garcia Centeno R, López-García MC, Lamas C, Álvarez-Escolá C, Calatayud Gutiérrez M, Blanco-Carrera C, de Miguel Novoa P, Valdés N, Gracia Gimeno P, Fernández-Ladreda MT, Mínguez Ojeda C, Percovich Hualpa JC, Mora M, Vidal Ó, Serrano Romero A, Hanzu FA, Gómez Dos Santos V. Risk factors for intraoperative complications in pheochromocytomas. Endocr Relat Cancer. 2021 Sep 08;28(11):695-703. doi: 10.1530/ERC-21-0230. PMID: 34379605.
Copy Download .nbib Format: NLM
Mutation in RyR2-FKBP Binding site alters Ca.

Cell calcium

Fernández-Morales JC, Xia Y, Renzo TJ, Zhang XH, Morad M.
PMID: 34813985
Cell Calcium. 2022 Jan;101:102500. doi: 10.1016/j.ceca.2021.102500. Epub 2021 Nov 08.

AIMS: To gain insights into FKBP regulation of cardiac ryanodine receptor (RyR2) and CaMETHODS AND RESULTS: CaCONCLUSIONS: The more frequent spontaneous Ca

Cite
Fernández-Morales JC, Xia Y, Renzo TJ, et al. Mutation in RyR2-FKBP Binding site alters Ca. Cell Calcium. 2021;101:102500doi: 10.1016/j.ceca.2021.102500.
Fernández-Morales, J. C., Xia, Y., Renzo, T. J., Zhang, X. H., & Morad, M. (2022). Mutation in RyR2-FKBP Binding site alters Ca. Cell calcium, 101102500. https://doi.org/10.1016/j.ceca.2021.102500
Fernández-Morales, José-Carlos, et al. "Mutation in RyR2-FKBP Binding site alters Ca." Cell calcium vol. 101 (2022): 102500. doi: https://doi.org/10.1016/j.ceca.2021.102500
Fernández-Morales JC, Xia Y, Renzo TJ, Zhang XH, Morad M. Mutation in RyR2-FKBP Binding site alters Ca. Cell Calcium. 2022 Jan;101:102500. doi: 10.1016/j.ceca.2021.102500. Epub 2021 Nov 08. PMID: 34813985; PMCID: PMC8752506.
Copy Download .nbib Format: NLM
Showing 901 to 904 of 904 entries